Novo Rebrand Sets Stage for Strategy Reset Against Lilly

The new logo is only the visible part of Novo Nordisk’s reset. The Danish drugmaker is also tightening the way it describes its business, shifting from Novo Nordisk to “Novo” in day-to-day operations while keeping Novo Nordisk A/S as its legal name.

The company unveiled the change on September 14, pairing it with the slogan “Lasting Health Starts Now” and a cultural framework called “The Novo Way.” Its four principles are customer obsession, competitiveness, clarity, and care and integrity. Novo said the framework is meant to produce faster decisions and a more consumer-focused organization without weakening its emphasis on scientific standards, ethics, or patient safety.

That language lands as Novo tries to recover momentum in the obesity-drug market, where Eli Lilly has narrowed the gap with Zepbound and is pushing its own oral treatments. Reuters reported that Novo’s Copenhagen-listed shares were down nearly 15% this year as investors weighed pipeline setbacks and pressure to produce another wave of blockbuster medicines. Last week, the company scrapped two late-stage trials of ziltivekimab, an experimental cardiovascular drug, adding to concerns about the depth of its development pipeline.

Commercially, the picture is less one-sided. Novo’s oral GLP-1 treatment has reportedly been gaining U.S. prescriptions faster than Lilly’s competing product, according to IQVIA data cited by an analyst. But the company needs durable growth beyond the current Wegovy and Ozempic franchise, especially as competition intensifies and insurers scrutinize the cost and convenience of obesity care.

The timing makes the rebrand more than a cosmetic exercise. Novo is scheduled to present an updated corporate strategy at its Capital Markets Day in London on September 21, when investors will look for evidence that the promised clarity and speed translate into capital allocation, pipeline execution, and stronger competition with Lilly.

A shorter name will not repair a weak trial or change prescription economics. It does signal how management wants the next phase understood: less institutional, more direct, and built around bringing its science closer to patients’ everyday lives.